These observations contrast with the outcomes of FF treatment in pathological settings, e.g., phospho-AMPK upregulation in hypertensive young rats [55] or increased protein levels of PPARα and PGC-1α in rabbits with atrial fibrillation [63]. The gene discussed is PPARA; the disease is atrial fibrillation.